Protease Inhibitors has 43 known drug interactions based on U.S. FDA drug labeling data. Of these, 10 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amiodarone Hydrochloride, Bromocriptine Mesylate, Dihydroergotamine Mesylate. Patients taking Protease Inhibitors should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 43
- Contraindicated
- 10
- Major
- 4
- Moderate
- 28
Contraindicated (10)
- Protease Inhibitors + Amiodarone Hydrochloride— Increased exposure of amiodarone via CYP450 inhibition. Avoid concomitant use.
- Protease Inhibitors + Bromocriptine Mesylate— Strong CYP3A4 inhibitors should be avoided with bromocriptine. Ensure adequate washout before initiating bromocriptine t…
- Protease Inhibitors + Dihydroergotamine Mesylate— CYP 3A4 inhibitors increase dihydroergotamine exposure; contraindicated per prescribing information.
- Protease Inhibitors + Ergotamine Tartrate— CYP 3A4 inhibitors contraindicated with ergotamine tartrate.
- Protease Inhibitors + Ergotamine Tartrate And Caffeine— Contraindicated per CONTRAINDICATIONS and WARNINGS as CYP 3A4 inhibitors.
- Protease Inhibitors + Ezetimibe And Simvastatin— Strong CYP3A4 inhibitors that increase simvastatin plasma levels, elevating risk of myopathy and rhabdomyolysis.
- Protease Inhibitors + Lovastatin— Strong CYP3A4 inhibitors increase risk of myopathy by reducing lovastatin elimination.
- Protease Inhibitors + Pimozide— Pimozide should not be administered concomitantly with protease inhibitors as inhibitors of CYP 3A4 metabolism.
- Protease Inhibitors + Simvastatin— Strong CYP3A4 inhibitors that increase simvastatin plasma levels, elevating risk of myopathy and rhabdomyolysis.
- Protease Inhibitors + Triazolam— Several HIV protease inhibitors are contraindicated with triazolam due to CYP 3A inhibition.
Major (4)
- Protease Inhibitors + Cyclophosphamide— Concomitant use may increase concentration of cytotoxic metabolites and enhance toxicities of cyclophosphamide, includin…
- Protease Inhibitors + Cyclophosphamide For Injection— Concomitant use may increase concentration of cytotoxic metabolites and enhance toxicities of cyclophosphamide, includin…
- Protease Inhibitors + Cyclophosphamide Injection, Solution— Protease inhibitors may increase concentration of cyclophosphamide cytotoxic metabolites, associated with higher inciden…
- Protease Inhibitors + Rifapentine— Rifapentine induces CYP450 enzymes, causing significant decrease in plasma concentrations and loss of therapeutic effect…
Moderate (28)
- Protease Inhibitors + Alosetron Hydrochloride— Strong CYP3A4 inhibitors that should be undertaken with caution due to potential for similar drug interactions with alos…
- Protease Inhibitors + Brincidofovir— OATP1B1/1B3 inhibitors increase brincidofovir AUC and Cmax, may increase adverse reactions. Monitor for elevations in tr…
- Protease Inhibitors + Carbamazepine— CYP3A4 inhibitors that increase carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustm…
- Protease Inhibitors + Drospirenone And Ethinyl Estradiol— May cause significant increases or decreases in plasma concentrations of estrogen and progestin.
- Protease Inhibitors + Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate Calcium— Significant changes (increase or decrease) in plasma concentrations of estrogen and progestin have been noted in some ca…
- Protease Inhibitors + Drospirenone/Ethinyl Estradiol/Levomefolate Calcium And Levomefolate Calcium— May cause significant changes (increase or decrease) in plasma concentrations of estrogen and progestin.
- Protease Inhibitors + Glimepiride— May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
- Protease Inhibitors + Glipizide— May reduce the glucose-lowering effect of glipizide, leading to worsening glycemic control. Monitor closely.
- Protease Inhibitors + Insulin Aspart Injection— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Aspart-Szjj— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Degludec— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Degludec And Liraglutide— May decrease blood glucose-lowering effect; dosage increases and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Detemir— May decrease blood glucose lowering effect of insulin detemir. Dosage increases and increased glucose monitoring may be …
- Protease Inhibitors + Insulin Glargine— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Glargine And Lixisenatide— May decrease the blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Glargine-Aglr— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Glargine-Yfgn— May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Glulisine— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Human— May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Lispro— May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
- Protease Inhibitors + Insulin Lispro-Aabc— May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
- Protease Inhibitors + Levonorgestrel/Ethinyl Estradiol And Ethinyl Estradiol— Significant changes in plasma levels of estrogen and progestin have been noted with co-administration.
- Protease Inhibitors + Maraviroc— CYP3A inhibitors including protease inhibitors (except tipranavir/ritonavir) increase maraviroc concentration; dosage ad…
- Protease Inhibitors + Medroxyprogesterone Acetate— Significant changes (increase or decrease) in plasma progestin levels may occur with co-administration.
- Protease Inhibitors + Mirtazapine— HIV protease inhibitors are potent CYP3A4 inhibitors that may increase mirtazapine concentrations. Caution should be exe…
- Protease Inhibitors + Nexterone (Amiodarone Hci)— May inhibit CYP450 enzymes, increasing amiodarone exposure and potential for interactions.
- Protease Inhibitors + Norethindrone Acetate, Ethinyl Estradiol And Ferrous Fumarate— May cause significant increases or decreases in plasma levels of estrogen and progestin, potentially decreasing contrace…
- Protease Inhibitors + Oxymetazoline Hydrochloride— Caution should be exercised when using alpha 1 adrenergic receptor antagonists with oxymetazoline.